Literature DB >> 15813894

Binding of endomorphin-2 to mu-opioid receptors in experimental mouse mammary adenocarcinoma.

J Fichna1, J-C do-Rego, M Mirowski, J Costentin, A Janecka.   

Abstract

Endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) binds with high affinity and selectivity to the mu-opioid receptor. In the present study, [125I]endomorphin-2 has been used to characterize mu-opioid-binding sites on transplantable mouse mammary adenocarcinoma cells. Cold saturation experiments performed with [125I]endomorphin-2 (1 nM) show biphasic binding curves in Scatchard coordinates. One component represents high affinity and low capacity (K(d) = 18.79 +/- 1.13 nM, B(max) = 635 +/- 24 fmol/mg protein) and the other shows low affinity and higher capacity (K(d) = 7.67 +/- 0.81 microM, B(max) = 157 +/- 13 pmol/mg protein) binding sites. The rank order of agonists competing for the [125I]endomorphin-2 binding site was [d-1-Nal3]morphiceptin > endomorphin-2 >> [d-Phe3]morphiceptin > morphiceptin > [d-1-Nal3]endomorphin-2, indicating binding of these peptides to mu-opioid receptors. The uptake of 131I-labeled peptides administered intraperitoneally to tumor-bearing mice was also investigated. The highest accumulation in the tumor was observed for [d-1-Nal3)morphiceptin, which reached the value of 8.19 +/- 1.14% dose/g tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813894     DOI: 10.1111/j.1399-3011.2005.00236.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  1 in total

1.  Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain.

Authors:  Y Wang; M O Nowicki; X Wang; W D Arnold; S A Fernandez; X Mo; J Wechuk; D Krisky; J Goss; D Wolfe; P G Popovich; S Lawler; E A Chiocca
Journal:  Gene Ther       Date:  2012-12-13       Impact factor: 5.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.